Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...

Affiliation “Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea” and “Cancer Research Institute, Seoul National University College of Medicine, ...

The FDA approved mitapivat (Aqvesme) as a disease-modifying treatment for anemia in adults with alpha- or beta-thalassemia, a rare inherited blood disease that affects hemoglobin production. An oral ...

Objectives To explore the experiences and perspectives of female patients with autoimmune rheumatic diseases (ARDs) regarding sexual and reproductive health, including contraception, family planning, ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR Therapeutics released a comprehensive clinical update on zugocaptagene geleucel ...

Company will host investor conference call and webcast tomorrow, December 24 at 8:00 a.m. ET CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a commercial-stage ...

CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...

Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported Monday that its investigational CD19-targeting allogeneic CAR T therapy, zugocaptagene geleucel (zugo-cel), has demonstrated ...